PROTAC-mediated CDK degradation differentially impacts cancer cell cycles due to heterogeneity in kinase dependencies.

Vishnu KumarasamyZhe GaoBosheng ZhaoBaishan JiangSeth M RubinKevin BurgessAgnieszka K WitkiewiczErik S Knudsen

Published in: British journal of cancer (2023)

Resistance to CDK4/6 inhibition could be overcome by pharmacologically limiting Cyclin E/CDK2 complex and proves to be a potential therapeutic approach.

Keyphrases

cell cycle
cell proliferation
single cell
tyrosine kinase